Beat-to-beat variability of repolarization: A new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs

Anadolu Kardiyoloji Dergisi

Volumn 7, Issue SUPPL. 1, 2007, Pages 73-78

  Oosterhoff, Peter ^a   Oros, Avram ^b   Vos, Marc A ^b  

^a MEDTRONIC BAKKEN RESEARCH CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Arrhythmias; Electrophysiology; Torsade de Pointes; Ventricular repolarization

Indexed keywords

4 (4 FLUOROPHENYL) 2 METHYL 6 (5 PIPERIDINOPENTYLOXY)PYRIMIDINE; AMIODARONE; AZITHROMYCIN; DOFETILIDE; MOXIFLOXACIN; SERTINDOLE; SOTALOL;

ARRHYTHMOGENESIS; ATRIOVENTRICULAR BLOCK; DISEASE ASSOCIATION; DISEASE SEVERITY; DOG; DRUG MEGADOSE; HEART ARRHYTHMIA; HEART BEAT; HEART FAILURE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; LOW DRUG DOSE; MORTALITY; NONHUMAN; PREDICTION; PROGNOSIS; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SCREENING TEST; SUDDEN DEATH; TACHYCARDIA; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; DEATH, SUDDEN, CARDIAC; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MYOCARDIAL CONTRACTION; RISK FACTORS; TORSADES DE POINTES; VENTRICULAR REMODELING;

EID: 34447102312     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Vos MA, Crijns HJ. Ventricular tachycardia in patients with hypertrophy and heart failure. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell To Bedside. Philadelphia: Saunders; 2004. p. 608-17.
2. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999; 42: 270-83.
3. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc Res 1998; 37: 324-34.
4. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998; 98: 2334-51.
5. Thomsen MB, Matz J, Volders PG, Vos MA. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 2006; 112: 150-70.
6. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47: 219-33.
7. Sykes R. Viewpoint: Sir Richard Sykes, DSc, FRS, FMedSci. Interview by Ingrid Torjesen, BSc. Circulation 2006; 113: 85-6.
8. Vos MA, de Groot SH, Verduyn SC, van der Zande J, Leunissen HD, Cleutjens JP, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 1998; 98: 1125-35.
9. Stengl M, Ramakers C, Donker DW, Nabar A, Rybin AV, Spatjens RL, et al. Temporal patterns of electrical remodeling in canine ventricular hypertrophy: focus on IKs downregulation and blunted beta-adrenergic activation. Cardiovasc Res 2006; 72: 90-100.
10. Schoenmakers M, Ramakers C, van Opstal JM, Leunissen JD, Londono C, Vos MA. Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc Res 2003; 59: 351-9.
11. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21: 1029-34.
12. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-34.
13. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994; 330: 235-41.
14. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006; 47: 362-7.
15. Antzelevitch C, Shimizu W, Yan GX, Sicouri S. Cellular basis for QT dispersion. J Electrocardiol 1998; 30 Suppl: 168-75.
16. Berger RD, Kasper EK, Baughman KL, Marban E, Calkins H, Tomaselli GF. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997; 96: 1557-65.
17. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004; 110: 2453-9.
18. Franz MR. Current status of monophasic action potential recording: theories, measurements and interpretations. Cardiovasc Res 1999; 41: 25-40.
19. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 1966; 59: 263-72.
20. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
21. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15: 475-95.
22. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-65.
23. Thomson MB, Oros A, Schoenmakers M, van Opstal JM, Maas JN, Beekman JD, et al. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 2007; 73: 521-30.
24. Thomsen MB, Beekman JD, Attevelt NJ, Takahara A, Sugiyama A, Chiba K, et al. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol 2006; 149: 1039-48.
25. Thomsen MB, Truin M, van Opstal JM, Beekman JD, Volders PG, Stengl M, et al. Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res Cardiol 2005; 100: 279-87.
26. Thomsen MB, Volders PG, Beekman JD, Matz J, Vos MA. Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. J Am Coll Cardiol 2006; 48: 1268-76.
27. Thomsen MB, Volders PG, Stengl M, Spatjens RL, Beekman JD, Bischoff U, et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther 2003; 307: 776-84.
28. van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, van Der Hulst FF, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104: 2722-7.
29. van Opstal JM, Verduyn SC, Leunissen HD, de Groot SH, Wellens HJ, Vos MA. Electrophysiological parameters indicative of sudden cardiac death in the dog with chronic complete AV-block. Cardiovasc Res 2001; 50: 354-61.
30. Winckels SKG, Thomson MB, Oosterhoff P, Oros A, Beekman J, Attevelt N, et al. High-septal pacing reduces electrical remodeling and arrhythmogeneity in the chronic atrioventricular block dog (Abstract). J Am Coll Cardiol 2006; 47 (4 Suppl 1): 25A-A.
31. Detre E, Thomson MB, Beekman JD, Petersen KU, Vos MA. Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes. Br J Pharmacol 2005; 145: 397-404.
32. Hinterseer M, Beckmann BM, Thomson MB, Pfeufer A, Perz S, Wichmann HE, et al. Beat-to-beat variability of QT intervals is increased in drug-induced and congenital long-QT syndromes (Abstract). Heart Rhythm 2006; 3 (Suppl 1): S269-70.
33. ICH-E14 ICH Harmonised Tripartite Guideline: The Clinical Evaluation of QT/QT c Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (ICH E14). 2005. Available at: URL: www.ich.org